The authors explicitly state the need to develop improved therapeutics targeting specific immunological disturbances and to diagnose patients before structural changes occur. Current immunotherapies have uncertain and incomplete efficacy for this condition. Gap type: open_question Source paper: Autoimmune encephalitis-associated epilepsy. (None, None, PMID:40316743)
Landscape Summary: What are the optimal therapeutic targets to prevent structural epileptogenesis in AEAE before inflammation resolves? is a 0.75 priority gap in neuroinflammation. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
What are the optimal therapeutic targets to prevent structural epileptogenesis in AEAE before inflammation resolves? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No knowledge graph edges recorded
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: